Affimed (NASDAQ:AFMD) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Affimed (NASDAQ:AFMD) in a report released on Tuesday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Several other brokerages have also recently weighed in on AFMD. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Affimed in a report on Tuesday, December 10th. Wells Fargo & Company decreased their price target on Affimed from $20.00 to $15.00 and set an “overweight” rating on the stock in a research report on Thursday, December 12th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, Affimed has a consensus rating of “Moderate Buy” and an average target price of $13.50.

Affimed Stock Down 1.8 %

Shares of AFMD opened at $0.71 on Tuesday. The company has a quick ratio of 1.93, a current ratio of 1.93 and a debt-to-equity ratio of 0.13. Affimed has a 12 month low of $0.70 and a 12 month high of $8.95. The firm’s 50 day moving average is $0.97 and its 200-day moving average is $2.04.

Institutional Trading of Affimed

Several institutional investors and hedge funds have recently modified their holdings of the business. Northern Trust Corp bought a new position in Affimed in the fourth quarter valued at about $218,000. Intellectus Partners LLC boosted its stake in shares of Affimed by 34.0% in the 4th quarter. Intellectus Partners LLC now owns 126,414 shares of the biopharmaceutical company’s stock valued at $150,000 after purchasing an additional 32,053 shares in the last quarter. Point72 Asset Management L.P. grew its holdings in shares of Affimed by 4.6% during the 3rd quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after purchasing an additional 15,108 shares during the last quarter. Jane Street Group LLC acquired a new position in Affimed during the 3rd quarter worth approximately $44,000. Finally, FMR LLC lifted its stake in Affimed by 30.0% in the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 4,086 shares during the last quarter. 30.82% of the stock is currently owned by institutional investors.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.